Ipamorelin vs CJC-1295 (No DAC)
How do Ipamorelin and CJC-1295 (No DAC) compare for Growth Hormone Axis research? Side-by-side evidence, molecular profile, EU legal status and COA-verified supplier prices — never dosing advice.
At a glance
Ipamorelin
CJC-1295 (No DAC)
Which fits which research target?
Both Ipamorelin and CJC-1295 (No DAC) sit within Growth Hormone Axis research but are studied for different primary signals. Neither is an approved medicine — compare the evidence, not marketing claims.
What the research shows
Ipamorelin
CJC-1295 (No DAC)
Compare prices across EU suppliers
Compare Ipamorelin across EU suppliers
16 EU vendors · COA · from €23.89
Compare CJC-1295 (No DAC) across EU suppliers
7 EU vendors · COA · from €23.89
Frequently asked questions
Is Ipamorelin or CJC-1295 (No DAC) better? ▾
Neither is an approved medicine, and “better” depends on the research target. Ipamorelin is most associated with GH pulse stimulation, while CJC-1295 (No DAC) is studied for Pulsatile GH release. Compare the evidence tiers and COA-verified EU pricing above rather than assuming one is superior. This is not a usage recommendation.
Why compare Ipamorelin and CJC-1295 (No DAC)? ▾
Both are studied within Growth Hormone Axis research through different mechanisms, so researchers often weigh them against each other. This page sets their evidence, molecular profile, EU legal status and supplier pricing side by side.
Which is cheaper in the EU, Ipamorelin or CJC-1295 (No DAC)? ▾
Prices vary by supplier, vial size and COA status. Ipamorelin is listed from €23.89 across 16 COA-verified EU vendors; CJC-1295 (No DAC) from €23.89 across 7. Open the price pages above to compare current listings — nobody pays us for placement.